Long-term follow-up of clinical trials of multiple sclerosis therapies

@article{Freedman2011LongtermFO,
  title={Long-term follow-up of clinical trials of multiple sclerosis therapies},
  author={Mark Steven Freedman},
  journal={Neurology},
  year={2011},
  volume={76},
  pages={S26 - S34}
}
Results from registry studies can provide valuable information about the prevalence and clinical course of different forms of multiple sclerosis (MS). Such studies can also help identify medical practice patterns in a real-world setting and important risk factors that may affect long-term outcomes in patients with MS. To date, however, these observational studies have provided less information than well-planned, randomized, controlled trials on the long-term treatment effects of disease… 
Real-World Effectiveness of Disease-Modifying Therapies in Korean Patients with Relapsing Multiple Sclerosis
TLDR
Real-world evidence is provided that DMTs are effective in reducing disease activity and disability progression in Korean MS patients and loss of NEDA3 at 2 years was associated with long-term disability progression.
Evaluating the potential benefit of interferon treatment in multiple sclerosis.
TLDR
The authors correctly conclude that they were not able to find evidence that administration of interferon beta was associated with a reduction in disability progression in patients with relapsing-remitting MS, which means that in the “real world” and with longer follow-up, the benefits of interFERon beta demonstrated in controlled trials are no longer relevant and that treatment with interferons beta should not be prescribed and reimbursed.
Clinical outcome measures in multiple sclerosis.
TLDR
The expanded disability status scale (EDSS) is the outcome measure that is most often included in MS studies but has serious weaknesses from a clinimetric point of view that limit its value as an outcome measure in MS.
Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis.
TLDR
Most of the factors associated with Interferon-β discontinuation are not modifiable, and are part of demographic features, or of disease characteristics, but should be taken into account when prescribing the first DMT for MS.
Outcome Measures in Clinical Trials for Multiple Sclerosis
TLDR
The historical background and recent developments of outcome measures in multiple sclerosis trials are provided, including newer assessments such as optical coherence tomography, biomarkers in body fluids and the concept of ‘no evidence of disease activity’ are discussed.
Multiple sclerosis: effect of beta interferon treatment on survival.
TLDR
Beta interferon treatment was associated with a lower mortality risk among people with relapsing-onset multiple sclerosis, consistent between two geographically distinct regions in North America and Europe.
Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice
TLDR
In this cohort, oral and injectable disease-modifying therapies were equally well tolerated, but teriflunomide appeared less effective for controlling multiple sclerosis activity than injectable therapies.
Improving adherence to injectable disease-modifying drugs in multiple sclerosis
  • A. Bayas
  • Medicine
    Expert opinion on drug delivery
  • 2013
TLDR
Improvements concerning drug delivery by innovative features could be achieved by the first electronic autoinjector RebiSmart™ and may help to increase adherence and the necessity of improving adherence to injectable disease-modifying drugs within the growing field of oral MS therapeutics will be discussed.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 59 REFERENCES
Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study.
TLDR
The design of and difficulties inherent in the execution of a long-term, observational trial that sought to assess the validity of short-term measures of multiple sclerosis (MS) (eg, relapse rate, inflammatory lesions) for long- term disease outcomes were described.
Course of multiple sclerosis
TLDR
First results from this study are reported on, covering 102 patients who were monitored for 2 years or more and examined regularly, and the individual progression of the disease as estimated using the linear regression coefficient did not correlate with the individual relapse rate.
Course of multiple sclerosis. First results of a prospective study carried out of 102 MS patients from 1976-1980.
TLDR
First results from this study are reported on, covering 102 patients who were monitored for 2 years or more and examined regularly, to quantify the extent of the worsening or improvement in the patients' clinical status over the period of observation using regression analysis techniques.
IM interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating event
TLDR
The results of a 5-year, open-label extension of CHAMPS indicate that there may be modest beneficial effects of immediate treatment compared with delayed initiation of treatment and support the use of IM interferon beta-1a after a first clinical demyelinating event.
Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate
TLDR
In conclusion, multiple sclerosis patients with mean disease duration of 22 years administering GA for up to 15 years had reduced relapse rates, and decreased disability progression and transition to SPMS.
Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis
TLDR
The MRI results demonstrate that IFNB has made a significant impact on the natural history of MS in these patients and support the clinical results in showing a significant reduction in disease activity as measured by numbers of active scans and appearance of new lesions.
The natural history of secondary progressive multiple sclerosis
TLDR
Three factors influencing the onset of SPMS in untreated patients with RRMS in British Columbia were identified: motor onset symptoms and male gender were associated with both a shorter time to and a younger age at SPMS, while a newer age at disease onset should not be viewed as indicating a better prognosis.
Eight-year follow-up study of brain atrophy in patients with MS
TLDR
Atrophy rate during the original trial was the most significant MRI predictor of disability status at follow-up and the relation between atrophy progression and subsequent neurologic disability status suggests thatatrophy progression during RRMS is clinically relevant, Therefore, atrophy progress may be a useful marker for disease progression in clinical trials.
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.
TLDR
Starting treatment with interferon beta-1a at the time of a first demyelinating event is beneficial for patients with brain lesions on MRI that indicate a high risk of clinically definite multiple sclerosis.
...
1
2
3
4
5
...